SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Yutaka Seino, Daisuke Yabe, Alogliptin benzoate for the treatment of type 2 diabetes, Expert Opinion on Pharmacotherapy, 2014, 15, 6, 851

    CrossRef

  2. 2
    Yutaka Seino, Takashi Sasaki, Atsushi Fukatsu, Michito Ubukata, Soichi Sakai, Yoshishige Samukawa, Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study, Current Medical Research and Opinion, 2014, 30, 7, 1231

    CrossRef

  3. 3
    Yutaka Seino, Takashi Sasaki, Atsushi Fukatsu, Michito Ubukata, Soichi Sakai, Yoshishige Samukawa, Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study, Current Medical Research and Opinion, 2014, 30, 7, 1245

    CrossRef

  4. 4
    Yutaka Seino, Takashi Sasaki, Atsushi Fukatsu, Soichi Sakai, Yoshishige Samukawa, Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study, Current Medical Research and Opinion, 2014, 30, 7, 1219

    CrossRef

  5. 5
    Yutaka Seino, Luseogliflozin for the treatment of type 2 diabetes, Expert Opinion on Pharmacotherapy, 2014, 15, 18, 2741

    CrossRef

  6. 6
    Y. Seino, Y. Miyata, S. Hiroi, M. Hirayama, K. Kaku, Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study, Diabetes, Obesity and Metabolism, 2012, 14, 10